Shares of Azenta, Inc. (NASDAQ:AZTA – Get Free Report) have earned an average rating of “Hold” from the seven brokerages that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $41.20.
A number of brokerages have recently weighed in on AZTA. Weiss Ratings upgraded Azenta from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. Needham & Company LLC raised their target price on shares of Azenta from $33.00 to $37.00 and gave the company a “buy” rating in a report on Wednesday.
Read Our Latest Report on AZTA
Institutional Inflows and Outflows
Azenta Price Performance
Shares of NASDAQ:AZTA opened at $31.76 on Thursday. The business’s 50 day simple moving average is $25.28 and its 200-day simple moving average is $25.55. The firm has a market capitalization of $1.46 billion, a price-to-earnings ratio of -11.51 and a beta of 1.37. Azenta has a 12 month low of $15.93 and a 12 month high of $41.73.
Azenta (NASDAQ:AZTA – Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.05. The firm had revenue of $161.18 million during the quarter, compared to analysts’ expectations of $149.31 million. Azenta had a positive return on equity of 1.15% and a negative net margin of 20.63%.
More Azenta News
Here are the key news stories impacting Azenta this week:
- Positive Sentiment: Strong quarterly beat: Azenta reported adjusted EPS of $0.16, topping the $0.11 analyst consensus, while revenue reached $161.18 million versus expectations of $149.31 million. The results signal better-than-expected operating performance and demand. Azenta Reports Third Quarter Results for Fiscal 2026
- Positive Sentiment: Raised revenue outlook: Azenta projected fiscal 2026 revenue of $613 million to $618 million, above the $597.3 million consensus estimate. The guidance suggests management expects growth to continue and supports the stronger earnings reaction.
- Positive Sentiment: Needham became more bullish: Needham & Company raised its price target from $33 to $37 and assigned a “Buy” rating, implying roughly 16.5% potential upside based on the reference price. Benzinga analyst rating report
- Positive Sentiment: Insider buying: Senior Vice President Ephraim Starr purchased 335 AZTA shares for approximately $8,097, modestly increasing his direct ownership. While small relative to the company’s market value, the purchase may reinforce confidence among investors. SEC insider transaction filing
- Neutral Sentiment: Valuation remains mixed: One analysis described Azenta as undervalued relative to sales but fairly valued based on cash flow, suggesting that the earnings beat and growth outlook are attractive but some of the optimism may already be reflected in the stock.
- Neutral Sentiment: Brokerage consensus: The average analyst target was reported at $40.40, providing additional potential upside, although target prices are estimates rather than guarantees. Azenta continues to report a negative net margin, which remains a financial risk despite the quarterly beat.
About Azenta
Azenta, Inc (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end‐to‐end sample tracking workflows.
In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next‐generation sequencing (NGS), DNA synthesis, and molecular biology services.
Featured Stories
- Five stocks we like better than Azenta
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.
